Scientific Committee
Francis Ayuk
Prof. Dr med.
University Medical Centre Hamburg-Eppendorf
I am a haemato-oncologist with special interest in cellular therapy. My research focuses on allogeneic transplantation and immune-effector cell therapies. I am currently deputy director and lead of cellular therapies of the department of stem cell transplantation at the university medical center in Hamburg.
Carolina Berger
Dr med.
University Medical Centre Hamburg-Eppendorf
CV of Dr Breithaupt-Grögler
Dr. Kerstin Breithaupt-Grögler (MD) studied medicine at J.W. Goethe-University Frankfurt, Germany (1976‑1983). After state approval as physician and medical thesis (doctor of medicine, summa cum laude) worked as Junior Research Fellow at Center of Physiology, University Frankfurt (1983-1985).
From 1986 to 1995 Research Physician / Clinical Investigator at Center of Cardiovascular Pharmacology, Mainz-Wiesbaden, Germany and Board Certification in Clinical Pharmacology. Since 1995 working as independent consultant in clinical pharmacology and medical writer. More than 20 years experience in planning, conduct, evaluation and reporting of clinical trials, writing of expert reports including safety dossiers, clinical summaries / overviews, scientific presentation and publication (30 original papers, more than 80 abstracts and oral presentations).
Founding member of the German Association of Applied Human Pharmacology (AGAH e.V., Hamburg), Board Member since 1997; President 2012-2014, Past President 2014-2018, since 2018 AGAH Regent / Consultant to the AGAH Board. AGAH Delegate to EUFEMED (European Federation for Exploratory Medicines Development, Brussels). Member of scientific programme committees, conduct of workshops and conferences, training courses in exploratory medicines development, qualification of study teams.
Maike Buchner
Dr rer. nat.
Max-Eder-Gruppenleader (Deutsche Krebshilfe)
Technical University of Munich
Maike Buchner completed her PhD with honors in 2010 in Freiburg and subsequently conducted her postdoctoral studies at UCSF, USA. Since 2016, her research on the dissection of divergent signaling events in malignant versus normal B-cells is supported by the Max-Eder-Program of the German Cancer Aid at the TU Munich.
Anjali Cremer
Dr med.
Max-Eder-Gruppenleader (Deutsche Krebshilfe)
University Hospital Frankfurt am Main
Anjali Cremer is an attending physician at the University Hospital Frankfurt. After her postdoctoral studies in the lab of Kimb Stegmaier at the Dana-Farber Cancer Institute, she started her own lab funded by the Max-Eder Program from the Deutsche Krebshilfe. Her strong translational focus is the identification of new targeted treatment options for difficult to treat leukemia subtypes by application of a proteogenomic approach.
Boris Fehse
Prof. Dr rer. nat.
University Medical Centre Hamburg-Eppendorf
CV of Dr Caplain
Dr. Henri Caplain, MD, MSc is a physician, senior adviser in early clinical development strategy and drug risk management. He is the past President of the ‘Association Française de Pharmacologie Translationnelle (AFPT) - Le Club Phase 1’ founding member of EUFEMED. After 15 years as primary investigator for early phase clinical trials and medical scientific director within an International CRO ‘Aster-Cephac Group’, he joined Sanofi-Synthelabo Research as head of clinical pharmacology and Exploratory, member of the R&D board. He became associate VP, deputy-head of worldwide clinical pharmacology for Sanofi-Aventis R&D, then head of the risk management center of excellence within Sanofi, member of the Benefit-Risk Assessment Committee chaired by the Sanofi Chief Medical Officer (CMO).
Stefan Horn
Dr rer. nat.
University Medical Centre Hamburg-Eppendorf
CV of Dr Caplain
Dr. Henri Caplain, MD, MSc is a physician, senior adviser in early clinical development strategy and drug risk management. He is the past President of the ‘Association Française de Pharmacologie Translationnelle (AFPT) - Le Club Phase 1’ founding member of EUFEMED. After 15 years as primary investigator for early phase clinical trials and medical scientific director within an International CRO ‘Aster-Cephac Group’, he joined Sanofi-Synthelabo Research as head of clinical pharmacology and Exploratory, member of the R&D board. He became associate VP, deputy-head of worldwide clinical pharmacology for Sanofi-Aventis R&D, then head of the risk management center of excellence within Sanofi, member of the Benefit-Risk Assessment Committee chaired by the Sanofi Chief Medical Officer (CMO).
Raphael Koch
Dr med.
Max-Eder-Gruppenleader (Deutsche Krebshilfe)
Medical Faculty of Goettingen
I am a hematologist and oncologist, head of the clinical trial office for hematology and oncology and translational research group leader at the University Medical Center of Göttingen. My research group focusses on the biology and functional vulnerabilities in T-cell neoplasms. I am speaker of the T-cell lymphoma working group of the German Lymphoma Alliance.
Nicolaus Kröger
Prof. Dr med. Dr h. c.
University Medical Centre Hamburg-Eppendorf
CV of Dr Caplain
Dr. Henri Caplain, MD, MSc is a physician, senior adviser in early clinical development strategy and drug risk management. He is the past President of the ‘Association Française de Pharmacologie Translationnelle (AFPT) - Le Club Phase 1’ founding member of EUFEMED. After 15 years as primary investigator for early phase clinical trials and medical scientific director within an International CRO ‘Aster-Cephac Group’, he joined Sanofi-Synthelabo Research as head of clinical pharmacology and Exploratory, member of the R&D board. He became associate VP, deputy-head of worldwide clinical pharmacology for Sanofi-Aventis R&D, then head of the risk management center of excellence within Sanofi, member of the Benefit-Risk Assessment Committee chaired by the Sanofi Chief Medical Officer (CMO).
Kristoffer Riecken
PD Dr rer. nat.
University Medical Centre Hamburg-Eppendorf
CV of Dr Caplain
Dr. Henri Caplain, MD, MSc is a physician, senior adviser in early clinical development strategy and drug risk management. He is the past President of the ‘Association Française de Pharmacologie Translationnelle (AFPT) - Le Club Phase 1’ founding member of EUFEMED. After 15 years as primary investigator for early phase clinical trials and medical scientific director within an International CRO ‘Aster-Cephac Group’, he joined Sanofi-Synthelabo Research as head of clinical pharmacology and Exploratory, member of the R&D board. He became associate VP, deputy-head of worldwide clinical pharmacology for Sanofi-Aventis R&D, then head of the risk management center of excellence within Sanofi, member of the Benefit-Risk Assessment Committee chaired by the Sanofi Chief Medical Officer (CMO).
Jasmin Wellbrock
PD Dr rer. nat.
University Medical Centre Hamburg-Eppendorf
CV of Dr Caplain
Dr. Henri Caplain, MD, MSc is a physician, senior adviser in early clinical development strategy and drug risk management. He is the past President of the ‘Association Française de Pharmacologie Translationnelle (AFPT) - Le Club Phase 1’ founding member of EUFEMED. After 15 years as primary investigator for early phase clinical trials and medical scientific director within an International CRO ‘Aster-Cephac Group’, he joined Sanofi-Synthelabo Research as head of clinical pharmacology and Exploratory, member of the R&D board. He became associate VP, deputy-head of worldwide clinical pharmacology for Sanofi-Aventis R&D, then head of the risk management center of excellence within Sanofi, member of the Benefit-Risk Assessment Committee chaired by the Sanofi Chief Medical Officer (CMO).
Important dates
January 2023
Start Abstract submission
February 13, 2023
Start Applicaton for Registration and
Start Stipend Application
March 31, 2023
Abstract submission deadline
March 31, 2023
Stipend application deadline
April 30, 2023
Abstract submission deadline (for Accepted Speakers)
June 24-27, 2023
XXIII. Wilsede-Meeting
Local Organising committee and Scientific Contact
Prof. Dr rer. nat Boris Fehse
Prof. Dr med. Dr h.c. Nicolaus Kröger
Universitätsklinikum Hamburg-Eppendorf
Clinic for Stem Cell Transplantation
Research Department Cell and Gene Therapy
Martinistrasse 52, Campus Forschung (N27)
20246 Hamburg
Meeting Office/Contact
Goernestraße 30
20249 Hamburg